Brief: Ssy Group Says Upadacitinib Obtains Registration Approval From NMPA
31/03/2026 02:31
March 31 (Reuters) - SSY Group Ltd 2005.HK: UPADACITINIB OBTAINS REGISTRATION APPROVAL FROM CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION Further company coverage: 2005.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on SSY
See all newsBrief: SSY Group Receives NMPA China Approval For Sodium Cromoglicate Eye Drops 2%
Brief: SSY Group Obtains NMPA Approval For Nimodipine Oral Solution
Brief: SSY Group Appoints Wu Heng Yao As Executive Director
Brief: SSY Group Says Ziprasidone Mesilate Receives Registration Approval In China
Hong Kong's SSY Group H1 profit rises on infusion solutions growth